Trovafloxacin treatment of viridans group Streptococcus experimental endocarditis

Antimicrob Agents Chemother. 2000 Sep;44(9):2554-6. doi: 10.1128/AAC.44.9.2554-2556.2000.

Abstract

The activity of trovafloxacin was compared with those of vancomycin and penicillin in a model of Streptococcus sanguis species group (trovafloxacin MIC, 0.125 microg/ml) and Streptococcus mitis species group (trovafloxacin MIC, 0.125 microg/ml) experimental endocarditis. Rabbits with catheter-induced aortic valve vegetations were given no treatment, trovafloxacin at 15 mg/kg of body weight three times a day (t.i.d.), vancomycin at 15 mg/kg twice a day, or penicillin at 1. 2 x 10(6) IU t.i.d. After 3 days of treatment, the animals were sacrificed; cardiac valve vegetations were aseptically removed and cultured quantitatively. Penicillin was as active as vancomycin as measured by in vivo clearance of bacteria. Trovafloxacin was less active (P < 0.05) than vancomycin or penicillin against S. sanguis species group infection but had similar efficacy against S. mitis species group infection. Quinolones, despite MICs in the susceptible range, may not be active for serious infections caused by some viridans group streptococci.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents / therapeutic use*
  • Disease Models, Animal
  • Endocarditis, Bacterial / drug therapy*
  • Fluoroquinolones*
  • Humans
  • Microbial Sensitivity Tests
  • Naphthyridines / therapeutic use*
  • Penicillins / therapeutic use
  • Rabbits
  • Streptococcal Infections / drug therapy*
  • Streptococcus / drug effects
  • Streptococcus / isolation & purification
  • Treatment Outcome
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Fluoroquinolones
  • Naphthyridines
  • Penicillins
  • Vancomycin
  • trovafloxacin